|
Name |
3-Deoxo-4b-deoxypaxilline
|
Molecular Formula | C27H35NO2 | |
IUPAC Name* |
2-[(1S,2S,5S,7S,11R,14S)-1,2-dimethyl-6-oxa-23-azahexacyclo[12.10.0.02,11.05,10.016,24.017,22]tetracosa-9,16(24),17,19,21-pentaen-7-yl]propan-2-ol
|
|
SMILES |
C[C@]12CC[C@H]3C(=CC[C@H](O3)C(C)(C)O)[C@@H]1CC[C@@H]4[C@@]2(C5=C(C4)C6=CC=CC=C6N5)C
|
|
InChI |
InChI=1S/C27H35NO2/c1-25(2,29)23-12-10-18-20-11-9-16-15-19-17-7-5-6-8-21(17)28-24(19)27(16,4)26(20,3)14-13-22(18)30-23/h5-8,10,16,20,22-23,28-29H,9,11-15H2,1-4H3/t16-,20-,22-,23-,26-,27+/m0/s1
|
|
InChIKey |
FDYCJJJTQUSEOV-HEPDKZGESA-N
|
|
Synonyms |
3-Deoxo-4b-deoxypaxilline; CHEMBL2408950; CHEBI:181374; 12-Demethyl-11,12-dehydropaspaline; C20534; 2-[(1S,2S,5S,7S,11R,14S)-1,2-dimethyl-6-oxa-23-azahexacyclo[12.10.0.02,11.05,10.016,24.017,22]tetracosa-9,16(24),17,19,21-pentaen-7-yl]propan-2-ol
|
|
CAS | NA | |
PubChem CID | 71745335 | |
ChEMBL ID | CHEMBL2408950 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 405.6 | ALogp: | 5.2 |
HBD: | 2 | HBA: | 2 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 45.2 | Aromatic Rings: | 6 |
Heavy Atoms: | 30 | QED Weighted: | 0.588 |
Caco-2 Permeability: | -4.689 | MDCK Permeability: | 0.00002270 |
Pgp-inhibitor: | 0.985 | Pgp-substrate: | 0.233 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.445 |
30% Bioavailability (F30%): | 0.064 |
Blood-Brain-Barrier Penetration (BBB): | 0.441 | Plasma Protein Binding (PPB): | 95.49% |
Volume Distribution (VD): | 1.626 | Fu: | 2.33% |
CYP1A2-inhibitor: | 0.35 | CYP1A2-substrate: | 0.72 |
CYP2C19-inhibitor: | 0.273 | CYP2C19-substrate: | 0.779 |
CYP2C9-inhibitor: | 0.454 | CYP2C9-substrate: | 0.093 |
CYP2D6-inhibitor: | 0.662 | CYP2D6-substrate: | 0.451 |
CYP3A4-inhibitor: | 0.947 | CYP3A4-substrate: | 0.654 |
Clearance (CL): | 7.947 | Half-life (T1/2): | 0.023 |
hERG Blockers: | 0.366 | Human Hepatotoxicity (H-HT): | 0.212 |
Drug-inuced Liver Injury (DILI): | 0.041 | AMES Toxicity: | 0.008 |
Rat Oral Acute Toxicity: | 0.959 | Maximum Recommended Daily Dose: | 0.962 |
Skin Sensitization: | 0.161 | Carcinogencity: | 0.85 |
Eye Corrosion: | 0.029 | Eye Irritation: | 0.051 |
Respiratory Toxicity: | 0.986 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002279 | 0.773 | D0H4JM | 0.301 | ||||
ENC005989 | 0.773 | D01JGV | 0.290 | ||||
ENC003172 | 0.773 | D0U7GP | 0.290 | ||||
ENC005406 | 0.703 | D02STN | 0.260 | ||||
ENC000857 | 0.654 | D08QKJ | 0.254 | ||||
ENC004710 | 0.642 | D0U3GL | 0.248 | ||||
ENC003933 | 0.613 | D0K0KH | 0.248 | ||||
ENC005990 | 0.611 | D06CNP | 0.244 | ||||
ENC005405 | 0.607 | D05MQK | 0.243 | ||||
ENC005988 | 0.595 | D0J1ML | 0.240 |